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Fibril formation has been considered a signiﬁcant feature of amyloid proteins. However, it has been
proposed that ﬁbril formation is a common property of many proteins under appropriate condi-
tions. We studied the ﬁbril formation of b-amylase, a non-amyloid protein rich in a-helical struc-
ture, because the secondary structure of b-amylase is similar to that of prions. With the
conditions for the ﬁbril formation of prions, b-amylase proteins were converted into amyloid ﬁbrils.
The features of b-amylase proteins and ﬁbrils are compared to prion proteins and ﬁbrils. Further-
more, the cause of neurotoxicity in amyloid diseases is discussed.
Structured summary of protein interactions:
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MoPrP and MoPrP bind by circular dichroism (View interaction)
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A variety of human diseases, including Alzheimer’s disease, type
II diabetes, and the spongiform encephalopathies such as Creutz-
feldt–Jakob disease, are associated with the extracellular deposi-
tion of insoluble protein aggregates known as amyloid ﬁbrils [1].
A study by Sunde and Blake using electron microscopy and X-ray
ﬁber diffraction indicates that the amyloid ﬁbrils associated with
various diseases all appear as unbranched straight ﬁbrils rich in
the cross-b structure formed by polypeptides oriented perpendicu-
lar to the long axis of the ﬁbrils [2]. Abundant experimental
evidence suggests that there is a strong link between ﬁbril forma-
tion and the onset of pathological symptoms [3].
Creutzfeldt–Jakob disease is caused by the misfolding of prion
protein (PrP). The normal, cellular form of PrP (PrPC) is highly
a-helical and sensitive to proteinase K, whereas the abnormal,
infectious, Scrapie isoform of PrP (PrPSc) is rich in b-sheet struc-
tures and resistant to proteinase K. PrPSc has a pronounced ten-
dency to misfold and to aggregate into highly stable insoluble
amyloid plaques. The mechanism of PrPSc formation has yet to be
fully elucidated.chemical Societies. Published by ECreutzfeldt–Jakob disease is a well-known amyloidosis. PrP, the
protein that is misfolded in Creutzfeldt–Jakob disease, is a large
protein with 231 amino acids. In previous in vitro experiments, re-
combinant mouse PrP (MoPrP) was converted into amyloid ﬁbrils
under incubation with guanidine hydrochloride (GdnHCl) [4].
These amyloid ﬁbrils induced PrPSc formation in mice [5]. Several
protein NMR structures of PrPs have been solved. The structure
of truncated MoPrP (121-231) consists of a primarily a-helical pro-
tein containing 52% a-helical structures and 3% b-sheet structures
(PDB 1AG2, [6]), as shown in Fig. 1A. Furthermore, the NMR
structure of hamster PrP (90-231) contains a ﬂexible N-terminus
and a structured C-terminal fragment (125-228) containing 43%
a-helical structures and 6% b-sheet structures (PDB 1B10, [7]).
The ﬂexibility of the N-terminus has been conﬁrmed in recombi-
nant full-length hamster PrP (29-231) [8].
While experimental observations suggest a strong link between
ﬁbril formation and the onset of disease, the origin of ﬁbril forma-
tion is still under debate. It is believed that the formation of amy-
loid ﬁbrils from speciﬁc proteins, such as PrP, give rise to
pathological symptoms. However, recent studies have shown that
ﬁbril formation might be common to many proteins rather than
a speciﬁc mechanism of proteins known to form ﬁbrils. For exam-
ple, the ﬁbril forms of lysozyme [9], the SH3 domain [10] and acyl
phosphatase [11] have been identiﬁed, but these ﬁbrils are notlsevier B.V. All rights reserved.
Fig. 1. (A) Structures of b-amylase (PDB 2XFR, [12]) and the C-terminus of MoPrP (PDB 1AG2, [6]). (B) Far-UV CD spectra of b-amylase and MoPrP in the absence and presence
of 2 M GdnHCl. (C) Heat-induced protein denaturation measured by the change of ellipticity at 222 nm. (D) Far-UV CD spectra of amyloid ﬁbrils.
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amyloid formation is not restricted to a small number of proteins,
but is a common property of many natural polypeptide chains un-
der appropriate conditions [11].
In this study, the conditions for the ﬁbril formation of PrP were
applied to b-amylase to determine if amyloid formation is a com-
mon property of many proteins. Previous X-ray diffraction studies
have indicated that b-amylase has 535 amino acids with 34% a-
helical and 11% b-sheet secondary structures ([12], Table 1). Paral-
lel experiments on PrP and b-amylase allow for a comparison of the
properties during ﬁbril formation of two a-helix-rich proteins. The
properties of b-amylase and MoPrP proteins were compared using
circular dichroism (CD) spectroscopy. The ﬁbrils formed by b-amy-
lase and MoPrP were characterized by CD spectroscopy, Congo red
staining, thioﬂavin T (ThT) binding assays and transmission elec-
tron microscopy (TEM) imaging.
2. Materials and methods
2.1. Materials
b-Amylase and lysozyme were purchased from Sigma Chemical
Company and used without further puriﬁcation after the purity
was veriﬁed by SDS–PAGE.
2.2. Protein expression and puriﬁcation
The plasmid pET101 encoding MoPrP (23-231) was transformed
into competent Escherichia coli BL21 (DE3) cells and expressed in
inclusion bodies. The protein was puriﬁed on a Ni-Sepharose col-
umn according to a previously described procedure [13]. The pur-
ity of the isolated protein was conﬁrmed by SDS–PAGE.2.3. Circular dichroism spectroscopy
The CD spectra of MoPrP and b-amylase were recorded with a
Jasco J-815 spectrometer. For measurements in the far-UV region,
a quartz cell with a path length of 0.1 cm was used. For the protein
samples, the concentrations of b-amylase and MoPrP were kept
constant at 8 and 10 lM, respectively, in 10 mM MES (pH 6.0).
For the ﬁbril samples, the concentrations of b-amylase and MoPrP
were recorded based on the starting protein concentration in the
ﬁbril conversion experiments. The concentrations of the scanned
ﬁbril samples for b-amylase and MoPrP were 16 and 10 lM,
respectively. For each sample, ﬁve scans were collected with a scan
speed of 50 nm per minute at 20 C. The heat-induced protein
denaturation experiment was conducted by heating the protein
solutions at a rate of 1 C/min, and the ellipticity at 222 nm was
measured every 0.5 C.
2.4. Fibril conversion experiments
Fibril conversion experiments were conducted with 40 lM pro-
tein (MoPrP, b-amylase or lysozyme) in a solution containing 2 M
GdnHCl and 50 mMMES (pH 6) at 37 C, as described in a previous
study on MoPrP ﬁbrils [4]. At the end of the experiment, the ﬁbril
samples were dialyzed with 20 mM sodium acetate (pH 5.5).
2.5. Congo red staining experiments
The visible spectrum of freshly prepared 50 lM Congo red solu-
tion was scanned with a Cary-50 UV–Vis spectrometer. The spectra
of Congo red-stained ﬁbril solutions were collected immediately
after the addition of the ﬁbrils. The images of Congo red and Congo
red-bound ﬁbrils were collected 10 min after the addition of the
Table 1
A comparison of prion and b-amylase proteins.
Number of residues Secondary structure Tm (C)
a-Helix a-Helix/GdnHCl b-Sheet
Prion 231 43%a (30%)c 14%c 6%a 69.1 c
b-Amylase 535 34%b (33%)c 14%c 11%b 62.6 c
a Calculation based on 142 residues [7].
b From Ref [12].
c This work.
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quots withdrawn from the Congo red binding assay were placed
onto a glass microscope slide for subsequent Congo red birefrin-
gence imaging.
The system for Congo red birefringence imaging consisted of a
light-emitting diode light source (Everlight Electronics), two polar-
izers (CVI Melles Griot), a x-y-z micro-positioning sample stage
with error less than 10 lm and a charge-coupled device
(Qimaging) for image capture.
2.6. ThT ﬂuorescence assay of ﬁbril conversion
Aliquots withdrawn during the time course of the ﬁbril conver-
sion at 37 C were diluted into 5 mM sodium acetate buffer (pH
5.5) to a ﬁnal sample concentration of 0.5 lM. ThT solution was
added to the aliquots at a ﬁnal concentration of 10 lM. For each
sample, two emission spectra were collected on a Hitachi F-4500
ﬂuorimeter. The ﬂuorescence spectra were recorded from 470 to
550 nm at an excitation wavelength of 450 nm. The maximum
ﬂuorescence emission at 482 nm was measured.
2.7. TEM
The ﬁbril samples were stained with 2% tungsten phosphoric
acid on carbon-coated 200-mesh copper grids. The samples were
adsorbed onto the copper grids for 30 s and subsequently washed
with PBS and mQH2O. The samples were air-dried before imaging.
The TEM images were collected using a Hitachi H-7100 TEM. The
analysis of ﬁbril length was performed with ImageJ software.
3. Results
3.1. Secondary structure and protein stability
Similar to MoPrP, b-amylase is an a-helical rich protein, as
shown in Fig. 1A. However, b-amylase is twice the molecular
weight of MoPrP. The abundance of a-helical structures in b-amy-
lase can be veriﬁed by CD spectroscopy (Fig. 1B); signals at both
208 and 222 nm indicate an a-helical structure. The a-helical con-
tent of the structure was calculated based on the following
equation:
a% ¼ ½h222
32000
ð1Þ
where [h]222 is the molar ellipticity at 222 nm. The calculated
a-helical content for b-amylase is 33%, which is consistent with a
previous structural analysis of this protein [12] (Table 1). When
b-amylase was exposed to 2 M GdnHCl, only 14% of the structure
remained a-helical (Fig. 1B). Similarly, the a-helical content of
MoPrP was calculated to be 30% in the absence of GdnHCl. This va-
lue is lower than the previously reported a-helical content [7] in a
different construct containing 142 residues. In this study, the
full-length MoPrP (23-231) was investigated, and the ratio of the
a-helical structures was calculated based on 208 residues. Because
the N-terminus is highly ﬂexible and does not contain anysecondary structural features [8], the calculated value for the
content of a-helical structure in full-length MoPrP was lower than
previously reported for the hamster PrP fragment (90-231). In the
presence of 2 M GdnHCl, only 14% of the a-helical structure was
preserved in MoPrP (Fig. 1B). The addition of 2 M GdnHCl unfolds
approximately half of the b-amylase and MoPrP structures.
PrP is known to be a highly stable protein. Therefore, we mea-
sured the stability of b-amylase in comparison to MoPrP by heat-
induced denaturation monitored by the change of ellipticity at
222 nm (Fig. 1C). The results of the heat-induced denaturation
were analyzed based on the Gibbs–Helmholtz equation:
DG

UðTÞ ¼ DHðTmÞ 1
T
Tm
 
 DGp ðTm  TÞ þ T ln
T
Tm
  
ð2Þ
Based on the above equation, the melting temperature (Tm) of
MoPrP and b-amylase were calculated to be 69.1 and 62.6 C,
respectively. A high Tm value for MoPrP is expected because PrP
is known to be a highly stable protein. The high Tm value for b-
amylase indicates that b-amylase is also a very stable protein.
Amyloid ﬁbrils are well-known for their cross-b-sheet struc-
tures. Therefore, the protein aggregates formed by MoPrP and b-
amylase were characterized by CD spectroscopy. The CD spectra
of b-amylase and MoPrP aggregate samples in the far-UV region
exhibited a clear signal at 217 nm, as shown in Fig. 1D, indicating
the presence of b-sheet structures in these ﬁbrils.
3.2. Fibril conversion
Fibril conversion from recombinant PrP has been achieved by
incubation with 2 M GdnHCl at 37 C. The formation of amyloid ﬁ-
brils can be characterized by many methods, including secondary
structure determination, a Congo red binding assay and birefrin-
gence imaging, a ThT-binding ﬂuorescence assay, and TEM [14].
Congo red has been an essential reagent in identifying amyloid
ﬁbrils; the early discovery of amyloid plaques was performed using
this dye. As shown in the inserted images in Fig. 2, Congo red mol-
ecules bind strongly to ﬁbril precipitates. Therefore, the color of a
Congo red solution is weakened after mixing with ﬁbrils. The
absorption spectra in Fig. 2A indicate that mixing Congo red with
MoPrP or b-amylase ﬁbrils caused the red-shift of kmax from 500
to 506 nm and caused a shoulder peak at 544 nm. These absorption
changes are consistent with previous reports for amyloid ﬁbrils
[15].
Another traditional hallmark of the presence of amyloid plaques
is the apple-green birefringence after Congo red staining when
viewed with polarized light [16]. The Congo red-stained ﬁbril sam-
ples were examined by polarized light microscopy. When two
polarizers were aligned, the stained samples appeared reddish pink
(Fig. 2B). When the polarizers were crossed at a right angle, green
spots appeared as a result of birefringence (Fig. 2C).
The ThT-binding ﬂuorescence assay is the most common assay
used to monitor the formation of amyloid ﬁbrils because the bind-
ing of ThT to amyloid ﬁbrils induces a signiﬁcant ﬂuorescence
emission at 482 nm. The increase in ﬂuorescence intensity typi-
cally represents the growth of the ﬁbrils. In the ﬁbril conversion
Fig. 2. (A) Congo red binding assay of b-amylase and MoPrP ﬁbrils. The inserted
image shows the Congo red solution (a) alone and (b) mixed with b-amylase ﬁbrils.
Birefringence of Congo red-stained ﬁbrils converted from b-amylase with (B)
aligned polarization and (C) crossed polarization at a right angle.
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within the ﬁrst two days (Fig. 3), indicating the growth of MoPrP
amyloid ﬁbrils. The ﬁbril conversion of lysozyme proceeded faster
than that of MoPrP; the ThT ﬂuorescence increased signiﬁcantly at
the end of the ﬁrst day. In contrast to MoPrP and lysozyme, the ThT
ﬂuorescence remained low after ﬁve days of b-amylase ﬁbril
conversion.
3.3. TEM imaging
MoPrP ﬁbrils were suspended before aliquots were drawn for
TEM imaging. For b-amylase ﬁbrils, aliquots were taken from the
precipitated ﬁbrils because of uncertainty in determining ﬁbril
abundance. Both MoPrP (Fig. 4A) and b-amylase (Fig. 4B) ﬁbrils
are unbranched, straight and long. The stacking of b-amylase ﬁbrils
is likely due to precipitation before their deposition onto TEM cop-
per grids.
An analysis of the length distribution of ﬁbrils is shown in
Fig. 4C and indicates that b-amylase ﬁbrils are primarily 200–
800 nm in length. MoPrP ﬁbrils showed a slightly wider distribu-Fig. 3. ThT-ﬂuorescence assay of ﬁbril conversion.tion range from 150 to 900 nm. The average length of the
b-amylase and MoPrP ﬁbrils was 463 and 518 nm, respectively.
Overall, b-amylase and MoPrP ﬁbrils formed under the same
conditions showed very similar morphology.4. Discussion
To examine whether amyloid ﬁbril formation is a feature of only
a few proteins found in the amyloid plaques that accumulate in
vivo, b-amylase was deliberately chosen for study based on its
structural similarity to MoPrP, a well-known amyloid protein.
The formation of amyloid ﬁbrils by recombinant PrP has been
studied in the presence of urea [17]. The shortest lag phase for ﬁ-
bril conversion was observed at partially denaturing conditions
which corresponds to the middle point of unfolding. In the pres-
ence of 2 M GdnHCl, both MoPrP and b-amylase are approximately
half-denatured, and only 14% of the a-helical structures are pre-
served. Therefore, the ﬁbril conversion of MoPrP and b-amylase
started from very similar folded states.
Nilsson has reviewed the techniques to study amyloid ﬁbril for-
mation in vitro and has concluded that a protein aggregate can be
classiﬁed as an amyloid ﬁbril if it satisﬁes some but not all of the
criteria [14]. In this study, b-sheet rich structures in the b-amylase
aggregates were characterized by CD spectroscopy. The results of
the Congo red binding assay, Congo red birefringence and TEM
were used to identify the features of the amyloid ﬁbrils and indi-
cated the formation of b-amylase ﬁbrils. However, the results of
the ThT-binding ﬂuorescence assay did not indicate the formation
of amyloid ﬁbrils. Previous studies suggest that amyloid ﬁbrils do
not always induce ThT ﬂuorescence. For example, some fragments
of TAR DNA-binding protein formed amyloid ﬁbrils based on TEM
images, but the binding of these ﬁbrils to ThT did not cause ﬂuores-
cence emission [18]. Based on the revised criteria for the identiﬁca-
tion of in vitro amyloid ﬁbrils by Nilsson [14], we conclude that b-
amylase forms amyloid ﬁbrils.
Similar to b-amylase, lysozyme is also rich in a-helical struc-
tures (38% a-helical and 10% b-sheet) [19]. The Tm value of b-amy-
lase is close to the Tm of lysozyme, which is 64.7 C [20]. The ﬁbril
formation of lysozyme has been well characterized [9]. We wanted
to determine if proteins with similar secondary structures and Tm
values were capable of conversion to amyloid ﬁbrils under the
same conditions. Thus, a ﬁbril conversion experiment was con-
ducted with lysozyme in the presence of 2 M GdnHCl at 37 C,
which are the same conditions used for MoPrP and b-amylase ﬁbril
formation. According to the results shown in Fig. 3, lysozyme is
converted to amyloid ﬁbrils under the conditions applied to MoPrP
and b-amylase. Based on the ﬁbril formation of a-helix rich pro-
teins, including MoPrP, b-amylase and lysozyme, under the same
conditions, we believe that proteins with similar protein structure
and stability might be capable of conversion to amyloid ﬁbrils un-
der the same conditions.
In the current study of b-amylase and MoPrP, both proteins
were half-denatured in the presence of 2 M GdnHCl. Starting from
these half-denatured states, both b-amylase and MoPrP were con-
verted to amyloid ﬁbrils even though b-amylase has never been
categorized as an amyloid protein. Taken together, these ﬁndings
and previous studies, which are not limited to amyloid proteins,
suggest that proteins in partially denatured states can potentially
be converted to amyloid ﬁbrils.
Conversion from PrPC to PrPSc, which is mediated by protein X,
has been considered as an essential step for the pathogenesis of
prion diseases [21]. In contrast, mediators have never been consid-
ered in the amyloid formation of other amyloid proteins. Because
the PrP protein is highly structured, we determined if a mediator
is required for highly structured proteins to form amyloid ﬁbrils.
Fig. 4. TEM images of ﬁbrils converted from (A) b-amylase and (B) MoPrP. The scale bar represents 1 lm. The magniﬁcation is noted. (C) Length distribution of b-amylase and
MoPrP ﬁbrils.
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structured b-amylase and lysozyme still form amyloid ﬁbrils.
Therefore, we question the necessity of a mediator for PrP to form
amyloid ﬁbrils; we suspect that a mediator is unnecessary for PrP
to form amyloid ﬁbrils.
Because non-amyloid proteins can potentially form ﬁbrils, we
have to consider the cause of neurotoxicity. Previous observations
demonstrating that substantial neurodegeneration in the absence
of PrPSc accumulation can occur in some cases of prion disease ar-
gues against the accumulation of PrPSc as the sole cause of pathol-
ogy [22,23]. In neurotoxic signaling studies, several mouse models
revealed that PrP can acquire a neurotoxic potential in the absence
of PrPSc/prion propagation [24]. Furthermore, b-sheet-rich con-
formers of completely different origins can induce apoptotic sig-
naling through PrPC [25]. These results are contradictory to the
traditional view that amyloid plaques rich with b-sheet structures
are the cause of neurotoxicity. The neurotoxic cause of amyloid
diseases needs to be revisited.
Previous studies have indicated that smaller aggregates of PrP
are more infectious than larger aggregates [26]. Other studies have
suggested that the neurotoxicity of Alzheimer’s disease is caused
by non-ﬁbrillar structures rather than mature ﬁbrils [27,28]. Sub-
sequent studies proposed that the formation of mature amyloid ﬁ-
brils is considered a protective mechanism that causes the removal
of the highly toxic pre-ﬁbrillar forms [29,30]. Because protein
aggregation is a property common to many proteins, the control
of protein homeostasis should be critically investigated as a step
toward combating amyloid diseases.Acknowledgements
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